Taysha Gene Therapies (TSHA) Assets Average (2020 - 2026)

Taysha Gene Therapies has disclosed Assets Average across 7 years of filings, most recently posting $321.8 million for Q1 2026.

• Assets Average for Q1 2026 came in at $321.8 million, up 115.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $321.8 million (up 115.47% YoY), and the FY2025 annual result was $251.8 million, up 51.21% from the prior year.
• Assets Average came in at $321.8 million for Q1 2026 at Taysha Gene Therapies, down from $329.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $329.9 million in Q4 2025 to a low of $91.6 million in Q2 2023.
• The 5-year median for Assets Average is $170.3 million (2024), against an average of $187.1 million.
• Across the five-year window, Assets Average plunged 47.75% in 2022 and soared 115.47% in 2026, its largest moves.
• Taysha Gene Therapies' Assets Average stood at $118.9 million in 2022, then jumped by 55.0% to $184.2 million in 2023, then retreated by 7.58% to $170.3 million in 2024, then surged by 93.75% to $329.9 million in 2025, then dropped by 2.46% to $321.8 million in 2026.
• The last three Assets Average figures came in at $321.8 million (Q1 2026), $329.9 million (Q4 2025), and $324.9 million (Q3 2025), per Business Quant data.